evidence based chronic disease self management education programs
Seven Clinics Cut Chronic Disease Management Gaps 70%
The CASTLE Phase 1/2 trial achieved a 76% improvement in daily functioning within three weeks, demonstrating that CD19 CAR-T therapy can safely deplete pathogenic B-cells for autoimmune patients. This breakthrough offers rapid symptom relief and a new pathway for chronic disease management, especially for those who have exhausted conventional